Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Comparable performance between automatic and manual laryngeal and hypopharyngeal GTV delineations validated with pathology.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiotherapy, University Medical Center Utrecht, Utrecht, The Netherlands.
Purpose: Deep learning is a promising approach to increase reproducibility and time-efficiency of GTV delineation in head and neck cancer, but model evaluation primarily relies on manual GTV delineations as reference annotation, which are subjective and tend to overestimate tumor volume. This study aimed to validate a deep learning model for laryngeal and hypopharyngeal GTV segmentation with pathology and to compare its performance with clinicians' manual delineations.
Materials And Methods: A retrospective dataset of 193 laryngeal and hypopharyngeal cancer patients was used to train a deep learning model with clinical GTV delineations as reference.
Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center's experience.
Front Oncol
December 2024
Clinic for Otorhinolaryngology, University Hospital Leipzig, Leipzig, Germany.
Introduction: The larynx organ preservation (LOP) trial DeLOS-II enrolled = 173 patients with advanced laryngeal/hypopharyngeal squamous cell carcinoma (LHSCC) amenable (only curatively resectable) through total laryngectomy (TL) to receive induction chemotherapy (IC) with TPF [docetaxel (T), cisplatin (P), and 5-fluorouracil (F)] (arm A, 85 patients) or additional cetuximab (E) weekly (arm B, 88 patients). Responders with endoscopic estimated tumor surface shrinkage (ETSS) ≥30% after 1 cycle IC (IC-1) received a further two cycles of IC followed by radiotherapy (RT), whereas TL was recommended for non-responders. Arm B failed to show superior 24-month laryngectomy-free survival (LFS) and overall survival (OS), the protocol-specified primary and secondary endpoints.
View Article and Find Full Text PDFAggressive Subtypes of Laryngeal Chondrosarcoma and their Clinical Behavior: A Systematic Review.
Oncol Ther
January 2025
Coordinator of the International Head and Neck Scientific Group, Padua, Italy.
Introduction: Laryngeal chondrosarcoma (CS) is a rare indolent malignant tumor. High-grade (G3), dedifferentiated (DD), and myxoid (MY) CSs are considered more aggressive subtypes due to their metastatic potential and relatively poor outcomes. The aim of this systematic review is to evaluate treatment modalities and survival outcomes in patients affected by these rarer CS subtypes.
View Article and Find Full Text PDFLymph Node Yield/Ratio, Neutrophil-Lymphocyte Ratio: Prognostic Factors in cN0 Laryngeal Carcinoma.
Laryngoscope
January 2025
Department of Otolaryngology - Head and Neck Surgery, Mansoura University, Mansoura, Egypt.
Objectives: The aim of this study was to investigate the role of lymph node yield (LNY), lymph node ratio (LNR), and neutrophil to lymphocyte ratio (NLR) as prognostic factors, their impact on survival in patients with advanced laryngeal squamous cell carcinoma (LSCC).
Methods: This multicentric retrospective study included 195 patients with clinical N0 advanced laryngeal carcinoma who underwent total laryngectomy and/or total pharyngolaryngectomy over 5 years. The number of lymph nodes extracted (LNY) and the number of positive nodes were counted.
Case report: Rare case of laryngeal hypertrophic lichen planus.
Int J Surg Case Rep
December 2024
Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne, 54519 Vandœuvre-lès-Nancy, France; CRAN, CNRS, UMR 7039, Université de Lorraine, Vandœuvre-lès-Nancy, France.
Introduction And Importance: Lichen planus is an inflammatory and chronic disease with multifactorial causes. Hypertrophic subtype of lichen planus is an extremely rare lesion when found in the larynx. This article describes the case of a man with such a lesion.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!